What drove the intraday fall in MDG1.F stock today?

The intraday drop was driven by thin liquidity and market pricing of Medigene’s ongoing liquidation. Volume was just **200** shares vs an avg **13,649**, amplifying moves. No major positive operational news offset the liquidation risk.

What is Meyka AI’s short-term price outlook for MDG1.F?

Meyka AI's forecast model projects a conservative 12-month target of **EUR 0.03**, implying **-28.23%** versus the current **EUR 0.0418**. Forecasts are model-based projections and not guarantees.

Is MDG1.F a liquid stock for intraday trading on XETRA?

No. MDG1.F has very low liquidity on XETRA with market cap **EUR 592,451** and recent volume **200**. Expect wide spreads, execution risk and volatile percentage moves on small orders.

What key dates should investors monitor for MDG1.F?

Watch the earnings/announcement on **26 Mar 2026** and any formal liquidation or asset-sale notices. Those filings will likely dictate the next meaningful price moves.

DE Stocks

MDG1.F -24.28% Medigene AG (XETRA) intraday 05 Feb 2026: liquidation risks ahead

ByDanny Kontos February 5, 2026February 5, 2026

MDG1.F stock dropped sharply 24.28% intraday on 05 Feb 2026, trading at EUR 0.0418 on XETRA as liquidity dried up and the company’s liquidation status weighed on buyers. Volume was just 200 shares versus an average of 13,649, magnifying price moves. The fall follows a small open at EUR 0.0396 and a prior close of EUR 0.0552, leaving the share price near its year low. Traders should treat intraday moves in Medigene AG with caution because low float, small market cap and ongoing liquidation can produce outsized swings.